Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Alamar Biosciences (ALMR) will report third-quarter 2026 financial results after market close on November 3, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alamar Biosciences (ALMR) will report third-quarter 2026 financial results after market close on November 3, 2026.
Management will host a webcast conference call at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Live audio will be available through the Investors section of www.alamarbio.com, with an archived replay available afterward.
Details
News Market Reaction – ALMR
On Oct 9, the first trading day after this news, ALMR closed 2.47% below the previous close. Argus tracked a trough of -2.6% from its starting point during tracking. Our momentum scanner recorded 18 alerts for this stock that day. Relative volume reached 2.9x the daily average during tracking.
Data tracked by StockTitan Argus for the Oct 9 session.
Key Figures
- Results report date
- November 3, 2026
- Third-quarter 2026 financial results, after market close
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREMONT, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report financial results for the third quarter 2026 after market close on Tuesday, November 3, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.alamarbio.com. The webcast will be archived and available for replay after the event.
About Alamar Biosciences, Inc.
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com.
Investor contact:
investors@alamarbio.com
Media contact:
media@alamarbio.com
